Advertisement

Endocrine Pathology

, Volume 29, Issue 3, pp 231–235 | Cite as

Reclassification as NIFTP: a Retrospective Review in a Single Institution with an Emphasis on Workload

  • Kevin O’Hare
  • E. O’Regan
  • A. Khattak
  • M. L. Healy
  • M. Toner
Article

Abstract

The aim of this study was to determine the number of cases of papillary thyroid carcinoma (PTC) which could be reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in our institute over a 10-year period, document their clinical status and assess the number of slides that had to be reviewed per case to exclude NIFTP. The histopathology reports for thyroid resections for all papillary carcinoma over a 10-year period (2007–2016) were reviewed. Five hundred forty-five histopathology reports were reviewed, and 71 cases were identified as potential cases of NIFTP. Forty-nine (69%) cases had been referred from external departments and the slides were not available for review. Of the remaining 22 (31% of 71) cases, 5 were reclassified as NIFTP. The 17 cases that were not reclassified as NIFTP required review of 114 of 356 slides (median 5.5 slides per case) was required to exclude NIFTP. For the 5 NIFTP cases, 58 slides were reviewed (median 12 slides per case). We found that review of the histology reports alone was adequate for exclusion in most cases, e.g. classic PTC or EVPTC cases with documented lymphovascular invasion or capsular invasion. As a single exclusion criterion is required for exclusion from reclassification as NIFTP, this can be achieved efficiently. Two of the five patients received radioactive iodine [RAI] as per standard treatment at time of diagnosis, on the basis of tumour size. None have recurrent or metastatic disease with mean follow-up of 5.8 years.

Keywords

Thyroid neoplasms Thyroid cancer Papillary carcinoma Papillary follicular/pathology Reclassification Follow-up 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

“For this type of study, formal consent is not required. This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors JAMA Oncology 2016 2[8]:1023–1029.  https://doi.org/10.1001/jamaoncol.2016.0386.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.Cancer. 2006;107[6]:1255–1264.  https://doi.org/10.1002/cncr.22138 CrossRefPubMedGoogle Scholar
  3. 3.
    Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol [Oxf]. 2006;65[3]:364–368.  https://doi.org/10.1111/j.1365-2265.2006.02605.x CrossRefGoogle Scholar
  4. 4.
    Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23[9]:1191–2000.  https://doi.org/10.1038/modpathol.2010.112 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25[9]:987–992.  https://doi.org/10.1002/cncy.21631 CrossRefPubMedGoogle Scholar
  6. 6.
    Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in the Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathology 2016;124[3]:181–187.  https://doi.org/10.1002/cncy.21631.CrossRefPubMedGoogle Scholar
  7. 7.
    Ganly I, Wang L, Tuttle RM, Katabi N, Ceballos GA, Harach HR, Ghossein R. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol 46:657–664.  https://doi.org/10.1016/j.humpath.2015.01.010
  8. 8.
    Rosario PW, Penna GC, Calsolari MR 2014 Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: is lobectomy sufficient for tumours <1 cm? Clin Endocrinol [Oxf] 81:630–632.  https://doi.org/10.1111/cen.12387 CrossRefGoogle Scholar
  9. 9.
    Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J. Encapsulated well-differentiated follicular patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol. 2010;34[6]:868–872.  https://doi.org/10.1097/PAS.0b013e3181efefed CrossRefPubMedGoogle Scholar
  10. 10.
    Titus K, CAP Today 2016 Issues, Article, July 2016Google Scholar
  11. 11.
    Likhterov I, Osorio M, Moubayed SP, Hernandez-Prera JC, Rhodes R, Urken ML. The Ethical Implications of the Reclassification of Noninvasive Follicular Variant Papillary Thyroid Carcinoma. Thyroid. 2016;26[9]:1167–1172.  https://doi.org/10.1089/thy.2016.0212 CrossRefPubMedGoogle Scholar
  12. 12.
    Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12[2]:160–174.  https://doi.org/10.1016/S1470-2045(11)70002-X CrossRefPubMedGoogle Scholar
  13. 13.
    Dekker J, Beekman A.T.F, Boenink A.D, Verheul H.M. Comment on ‘Psychological distress in patients with cancer: is screening the effective solution?’. Br J Cancer. 2013 108[12]: 2628–2630.  https://doi.org/10.1038/bjc.2013.286.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Buchmann L, Ashby S, Cannon RB, Hunt JP. Psychosocial distress in patients with thyroid cancer. Otolaryngol Head Neck Surg. 2015;152[4]:644–649CrossRefPubMedGoogle Scholar
  15. 15.
    Agrawal N, Abbott CE, Liu C, Kang S, Tipton L, Patel K, Persky M, King L, Deng FM, Bannan M, Ogilvie JB,Heller K, Hodak SP. Non invasive follicular tumour with papillary like nuclear features: not a tempest in a teapot. Endocr Pract 2017 23[4] 451–457.  https://doi.org/10.4158/EP161632.OR CrossRefPubMedGoogle Scholar
  16. 16.
    Parente DN, Kluijfhout WP, Bongers PJ, Verzijl R, Devon KM, Rotstein LE, Goldstein DP, Asa SL, Mete O, Pasternak JD. Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign? World J Surg. 2018;42[2]:321–326.  https://doi.org/10.1007/s00268-017-4182-5 CrossRefPubMedGoogle Scholar
  17. 17.
    Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30[6]:810–825.  https://doi.org/10.1038/modpathol.2017.9 CrossRefPubMedGoogle Scholar
  18. 18.
    Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28[10]:1336–1340.CrossRefPubMedGoogle Scholar
  19. 19.
    Lester DR. Thompson Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol. 2016;29[7]:698–707.  https://doi.org/10.1038/modpathol.2016.65 CrossRefGoogle Scholar
  20. 20.
    Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. Endocr Pathol. 2017;28[2]:171–176.  https://doi.org/10.1007/s12022-017-9476 CrossRefPubMedGoogle Scholar
  21. 21.
    Kiernan CM, Weiss VL, Mehrad M, Ely K, Baregamian N, Solórzano CC. New terminology-noninvasive follicular neoplasm with papillary-like nuclear features [NIFTP] and its effect on the rate of malignancy at a single institution. Surgery. 2018;163[1]:55–59.  https://doi.org/10.1016/j.surg.2017.04.041 CrossRefPubMedGoogle Scholar
  22. 22.
    Du Jour, Schmitt, Chen AY, Griffith CC. Application of Strict Criteria for Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Encapsulated Follicular Variant Papillary Thyroid Carcinoma: a Retrospective Study of 50 Tumors Previously Diagnosed as Follicular Variant PTC. Endocr Pathol. 2018 ;29[1]:35–42.  https://doi.org/10.1007/s12022-017-9509-0 CrossRefPubMedGoogle Scholar
  23. 23.
    Maletta F, Massa F, Torregrossa L. Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol. 2016;54:134–142.  https://doi.org/10.1016/j.humpath.2016.03.014 CrossRefPubMedGoogle Scholar
  24. 24.
    Zhou H, Baloch ZW, Nayar R Noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]: Implications for the risk of malignancy [ROM] in the Bethesda System for Reporting Thyroid Cytopathology [TBSRTC] Cancer. 2018;126[1]:20–26.  https://doi.org/10.1002/cncy.21926 CrossRefGoogle Scholar
  25. 25.
    Z W Baloch, R R. Seethala, W C. Faquin, Noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]: A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathol. 2016 ;124[9]:616-620.  https://doi.org/10.1002/cncy.21744 CrossRefPubMedGoogle Scholar
  26. 26.
    Xu B, Tallini G, Ghossein RA. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges. Endocr Pathol. 2017;28[2]:128–138.  https://doi.org/10.1007/s12022-017-9478-3 CrossRefPubMedGoogle Scholar
  27. 27.
    Hassan MH Kamel Trends and Challenges in Pathology Practice Choices and necessities Sultan Qaboos Univ Med J. 2011; 11[1]: 38–44.Google Scholar
  28. 28.
    Cloetingh D, Schmidt RA, Kong CS Comparison of Three Methods for Measuring Workload in Surgical Pathology and Cytopathology. Am J Clin Pathol. 2017;148[1]:16–22.  https://doi.org/10.1093/ajcp/aqx022 CrossRefPubMedGoogle Scholar
  29. 29.
    The Royal College of Pathologists Guidelines on staffing and workload for histopathology and cytopathology departments [4th edition] September 2015Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HistopathologySt. James HospitalDublinIreland
  2. 2.Department of Oral and Maxillofacial Surgery, Medicine and PathologyDublin Dental University HospitalDublinIreland
  3. 3.Department of EndocrinologySt. James HospitalDublinIreland

Personalised recommendations